Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Evommune (EVMN) Share-based Compensation (2024 - 2025)

Evommune (EVMN) has disclosed Share-based Compensation for 2 consecutive years, with $4.2 million as the latest value for Q4 2025.

  • Quarterly Share-based Compensation rose 749.39% to $4.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.7 million through Dec 2025, changed N/A year-over-year, with the annual reading at $5.9 million for FY2025, 240.07% up from the prior year.
  • Share-based Compensation for Q4 2025 was $4.2 million at Evommune, up from $561000.0 in the prior quarter.
  • The five-year high for Share-based Compensation was $4.2 million in Q4 2025, with the low at $401000.0 in Q3 2024.